Browsing tag:


Pfizer and GlaxoSmithKline Combat Melanoma An announcement was made by pharmaceutical giants Pfizer and GlaxoSmithKline at the end of November 2013 regarding their agreement to combine efforts in researching a novel melanoma treatment. The clinical study the two companies have commenced involves adult patients with unresectable, metastatic melanoma. This partnership will be a Phase I/II[…]

Read More

At the 28th Annual EAU Congress, held in mid- March 2013 some startling statistic regarding men suffering from Erectile Dysfunction were revealed. Known also as ED, Erectile Dysfunction plagues almost 88 million men worldwide.  Shocking numbers from a large clinical study of a subset of these patients, specifically a little over 6 million men, showed[…]

Read More

On Wednesday January 26, 2011, GlaxoSmithKline (GSK) announced that the Company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the supplemental New Drug Application (sNDA) for Avodart® (Dutasteride CAS# 164656-23-9 available for R&D purposes from LGM Pharma, a US based API supplier) for reducing the risk of prostate[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service